



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In application of:

Thomas R. COOLIDGE *et al.*

Group Art Unit: 1653

Appln. No.: 09/851,738

Examiner: Samuel W. LIU

Filed: May 9, 2001

Atty. Docket: 18528.613 / 0213-DIV-9

For: **Metabolic Intervention with GLP-1
to Improve the Function of Ischemic
and Reperfused Tissue**

Confirmation No. 4849

INFORMATION DISCLOSURE STATEMENT

Mail Stop RCE

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

The attention of the Examiner is invited to the documents listed on the attached Form PTO-1449. Copies of the listed documents are submitted herewith.

It is respectfully requested that the information above be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom. However, Applicants make no representation or admission that the cited references constitute "prior art" to the claims of the present application.

Further, Applicants wish to bring to the attention of the Examiner, the following co-pending applications:

1. U.S. Application No. 10/091,258
Filed: March 5, 2002
Entitled: Compositions and Methods for Treating Peripheral Vascular Disease; and
2. U.S. Application No. 10/913,309
Filed: August 6, 2004
Entitled: Metabolic Intervention with GLP-1 or its Biologically Active Analogue to Improve the Function of the Ischemic and Reperfused Brain

Thomas R. COOLIDGE *et al.*
Appln. No. 09/851,738
Page 2

CERTIFICATION AND/OR FEE

Because this Information Disclosure Statement is being submitted after issuance of the first action on the merits of the above-captioned application, a fee of \$180.00 is due pursuant to 37 C.F.R. § 1.17(p). Applicants request that this fee be charged to Deposit Account No. 50-2387 referencing docket number 18528.613.


Respectfully submitted,



David R. Marsh (Reg. No. 41,408)
Rachel L. Adams (Reg. No. 54,660)

Date: June 3, 2005

ARNOLD & PORTER LLP
555 Twelfth Street, N.W.
Washington, D.C. 20004-1206
(202) 942-5000 telephone
(202) 942-5999 facsimile



FORM PT 609-49
PATENT INFORMATION ENCLOSURE STATEMENT

ATTY. DOCKET NO.

18528.613 / 0213-DIV-9

APPLICATION NO.

09/851,738

APPLICANTS

Thomas R. COOLIDGE *et al.*

FILING DATE

May 9, 2001

GROUP

1653

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA1	4,976,959	12/1990	Berger, Jr., <i>et al.</i>			
	AB1	2002/0061838 A1	5/2002	Holmquist <i>et al.</i>			
	AC1						
	AD1						
	AE1						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AF1	98/43658	10/1998	PCT			Yes No
	AG1	00/16797	3/2000	PCT			Yes No
	AH1						Yes No
	AI1						Yes No
	AJ1						Yes No


OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AK1	Abbott <i>et al.</i> , "The Impact of Diabetes on Survival Following Myocardial Infarction in Men vs. Women - The Framingham Study", <u>JAMA</u> , Vol. 260 No. 23, pp. 3456-3460 (1988)
	AL1	Bhat <i>et al.</i> , "Skeletal Muscle Mitochondrial DNA Injury in Patients With Unilateral Peripheral Arterial Disease", <u>Circulation</u> , Vol. 99, pp. 807-812 (1999)
	AM1	Boska <i>et al.</i> , " ³¹ P MRS Studies of Exercising Human Muscle at High Temporal Resolution", <u>Magnetic Resonance in Medicine</u> , Vol. 41, pp. 1145-1151 (1999)
	AN1	Brand <i>et al.</i> , "Diabetes, Intermittent Claudication, and Risk of Cardiovascular Events - The Framingham Study", <u>Diabetes</u> , Vol. 38, pp. 504-509 (1989)
	AO1	Bullock <i>et al.</i> , "Tissue Distribution of Messenger Ribonucleic Acid Encoding the Rat Glucagon-Like Peptide-1 Receptor", <u>Endocrinology</u> , Vol. 137, No. 7, pp. 2968-2978 (1996)
	AP1	Clanton <i>et al.</i> , "Physiological and Genomic Consequences of Intermittent Hypoxia Invited Review: Adaptive Responses of Skeletal Muscle to Intermittent Hypoxia: the Known and the Unknown", <u>J. Appl. Physiol.</u> , Vol. 90, pp. 2476-2487 (2001)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449
INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.

18528.613 / 0213-DIV-9

APPLICATION NO.

09/851,738

APPLICANTS

Thomas R. COOLIDGE *et al.*

FILING DATE

May 9, 2001

GROUP

1653

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AA2

Dawson *et al.*, "A Comparison of Cilostazol and Pentoxifylline for Treating Intermittent Claudication", The American Journal of Medicine, Vol. 109, pp. 523-530

AB2

DuPont *et al.*, "Marijuana and Benzodiazepines in Patients Receiving Methadone Treatment", JAMA, Vol. 261, No. 23, pp. 3409 (1989)

AC2

Gray *et al.*, "Risk Factor Clustering in the Insulin Resistance Syndrome - The Strong Heart Study", American Journal of Epidemiology, Vol. 147, No. 9, pp. 869-878 (1998)

AD2

Green, "Regarding 'Phosphorus 31 Nuclear Magnetic Resonance Spectroscopy Suggests a Mitochondrial Defect in Claudicating Skeletal Muscle' ", Journal of Vascular Surgery Online, Vol. 33, No. 5, pp. 1-2 (2001)

AE2

Hamilton *et al.*, "Insulin Reduction of Cerebral Infarction Due to Transient Focal Ischemia", J. Neurosurg., Vol. 82, pp. 262-268 (1995)

AF2

Hiatt *et al.*, "Carnitine Metabolism During Exercise in Patients with Peripheral Vascular Disease", J. Appl. Physiol., Vol. 62, No. 6, pp. 2383-2387 (1987)

AG2

Iribarren *et al.*, "Glycemic Control and Heart Failure Among Adult Patients with Diabetes", Circulation, Vol. 103, pp. 2668-2673 (2001)

AH2

Irwin *et al.*, "The *Xenopus* proglucagon gene encodes novel GLP-1-like peptides with insulinotropic properties", Proc. Natl. Acad. Sci. USA, Vol. 94, pp. 7915-7920 (1997)

AI2

Matz, "Does Control of Diabetes Prevent Vascular Complications?", JAMA, Vol. 261, No. 23, pp. 3409-3410 (1989)

AJ2

Reilly *et al.*, "Cilostazol: Treatment of Intermittent Claudication", The Annals of Pharmacotherapy, Vol. 35, pp. 48-56 (2001)

AK2

Scott *et al.*, "Glucose and Insulin Therapy in Acute Stroke; Why Delay Further?", Q J Med, Vol. 91, pp. 511-515 (1998)


AL2

Serre *et al.*, "Exendin-(9-39) is an Inverse Agonist in the Murine Glucagon-Like Peptide-1 Receptor: Implications for Basal Intracellular Cyclic Adenosine 3',5'-Monophosphate Levels and β -Cell Glucose Competence", Endocrinology, Vol. 139, No. 11, pp. 4448-4454 (1998)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449
INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO. 18528.613 / 0213-DIV-9	APPLICATION NO. 09/851,738
APPLICANTS Thomas R. COOLIDGE <i>et al.</i>	
FILING DATE May 9, 2001	GROUP 1653

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AA3	Sissman <i>et al.</i> , "Patent Ductus Arteriosus, Prematurity, and Respiratory Distress Syndrome", <u>JAMA</u> , Vol. 261, No. 23, pp. 3410 (1989)
AB3	Weitz <i>et al.</i> , "Diagnosis and Treatment of Chronic Arterial Insufficiency of the Lower Extremities: A Critical Review", <u>Circulation</u> , Vol. 94, pp. 3026-3049 (1996)
AC3	
AD3	
AE3	
AF3	
AG3	
AH3	
AI3	
AJ3	
AK3	
AL3	

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.